Recent News

• 09.02.2025 - Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
• 08.27.2025 - Alpha Tau to Participate in Five September Investor Conferences
• 08.12.2025 - Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
• 07.10.2025 - Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical PromiseAn interview with Prof. Aron Popovtzer
• 05.28.2025 - Alpha Tau to Present at Jefferies Global Healthcare Conference
• 05.20.2025 - Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.27.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.11.2025 - EX-99.1 EX-99.1
• 07.24.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.02.2025 - EFFECT Notice of Effectiveness
• 06.30.2025 - CORRESP Correspondence
• 06.27.2025 - UPLOAD SEC-generated letter